Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Mar;65(3):1045–1052. doi: 10.1128/iai.65.3.1045-1052.1997

Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

S J Devi 1, W D Zollinger 1, P J Snoy 1, J Y Tai 1, P Costantini 1, F Norelli 1, R Rappuoli 1, C E Frasch 1
PMCID: PMC175086  PMID: 9038314

Abstract

We reported the first use of group B meningococcal conjugate vaccines in a nonhuman primate model (S. J. N. Devi, C. E. Frasch, W. Zollinger, and P. J. Snoy, p. 427-429, in J. S. Evans, S. E. Yost, M. C. J. Maiden, and I. M. Feavers, ed., Proceedings of the Ninth International Pathogenic Neisseria Conference, 1994). Three different group B Neisseria meningitidis capsular polysaccharide (B PS)-protein conjugate vaccines and an Escherichia coli K92 capsular polysaccharide-tetanus toxoid (K92-TT) conjugate vaccine are here evaluated for safety and relative immunogenicities in juvenile rhesus monkeys with or without adjuvants. Monkeys were immunized intramuscularly with either B PS-cross-reactive material 197 conjugate, B PS-outer membrane vesicle (B-OMV) conjugate, or N-propionylated B PS-outer membrane protein 3 (N-pr. B-OMP3) conjugate vaccine with or without adjuvants at weeks 0, 6, and 14. A control group of monkeys received one injection of the purified B PS alone, and another group received three injections of B PS noncovalently complexed with OMV. Antibody responses as measured by enzyme-linked immunosorbent assay varied among individual monkeys. All vaccines except B PS and the K92-TT conjugate elicited a twofold or greater increase in total B PS antibodies after one immunization. All vaccines, including the K92-TT conjugate, elicited a rise in geometric mean B PS antibody levels of ninefold or more over the preimmune levels following the third immunization. Antibodies elicited by N-pr. B-OMP3 and B-OMV conjugates were directed to the N-propionylated or to the spacer-containing B PS antigens as well as to the native B PS complexed with methylated human serum albumin. None of the vaccines caused discernible safety-related symptoms.

Full Text

The Full Text of this article is available as a PDF (164.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arakere G., Frasch C. E. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect Immun. 1991 Dec;59(12):4349–4356. doi: 10.1128/iai.59.12.4349-4356.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azmi F. H., Lucas A. H., Spiegelberg H. L., Granoff D. M. Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain. Infect Immun. 1995 May;63(5):1906–1913. doi: 10.1128/iai.63.5.1906-1913.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartoloni A., Norelli F., Ceccarini C., Rappuoli R., Costantino P. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine. 1995 Apr;13(5):463–470. doi: 10.1016/0264-410x(94)00007-a. [DOI] [PubMed] [Google Scholar]
  4. Bortolussi R., Ferrier P. Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen. Infect Immun. 1980 Apr;28(1):111–117. doi: 10.1128/iai.28.1.111-117.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bulkow L. R., Wainwright R. B., Letson G. W., Chang S. J., Ward J. I. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J. 1993 Jun;12(6):484–492. doi: 10.1097/00006454-199306000-00006. [DOI] [PubMed] [Google Scholar]
  6. Cadoz M., Armand J., Arminjon F., Gire R., Lafaix C. Tetravalent (A, C, Y, W 135) meningococcal vaccine in children: immunogenicity and safety. Vaccine. 1985 Sep;3(3):340–342. doi: 10.1016/s0264-410x(85)90266-x. [DOI] [PubMed] [Google Scholar]
  7. Campbell H., Byass P., Ahonkhai V. I., Vella P. P., Greenwood B. M. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics. 1990 Jul;86(1):102–107. [PubMed] [Google Scholar]
  8. Devi S. J., Karpas A. B., Frasch C. E. Binding diversity of monoclonal antibodies to alpha(2-->8) polysialic acid conjugated to outer membrane vesicle via adipic acid dihydrazide. FEMS Immunol Med Microbiol. 1996 Jul;14(4):211–220. doi: 10.1111/j.1574-695X.1996.tb00289.x. [DOI] [PubMed] [Google Scholar]
  9. Devi S. J., Robbins J. B., Schneerson R. Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7175–7179. doi: 10.1073/pnas.88.16.7175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Devi S. J., Schneerson R., Egan W., Vann W. F., Robbins J. B., Shiloach J. Identity between polysaccharide antigens of Moraxella nonliquefaciens, group B Neisseria meningitidis, and Escherichia coli K1 (non-O acetylated). Infect Immun. 1991 Feb;59(2):732–736. doi: 10.1128/iai.59.2.732-736.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Finne J., Leinonen M., Mäkelä P. H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983 Aug 13;2(8346):355–357. doi: 10.1016/s0140-6736(83)90340-9. [DOI] [PubMed] [Google Scholar]
  12. Finne J. Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. J Biol Chem. 1982 Oct 25;257(20):11966–11970. [PubMed] [Google Scholar]
  13. Frasch C. E., Zahradnik J. M., Wang L. Y., Mocca L. F., Tsai C. M. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J Infect Dis. 1988 Oct;158(4):710–718. doi: 10.1093/infdis/158.4.710. [DOI] [PubMed] [Google Scholar]
  14. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Griffiss J. M., Brandt B. L., Altieri P. L., Pier G. B., Berman S. L. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect Immun. 1981 Dec;34(3):725–732. doi: 10.1128/iai.34.3.725-732.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Husmann M., Roth J., Kabat E. A., Weisgerber C., Frosch M., Bitter-Suermann D. Immunohistochemical localization of polysialic acid in tissue sections: differential binding to polynucleotides and DNA of a murine IgG and a human IgM monoclonal antibody. J Histochem Cytochem. 1990 Feb;38(2):209–215. doi: 10.1177/38.2.1688896. [DOI] [PubMed] [Google Scholar]
  17. Häyrinen J., Bitter-Suermann D., Finne J. Interaction of meningococcal group B monoclonal antibody and its Fab fragment with alpha 2-8-linked sialic acid polymers: requirement of a long oligosaccharide segment for binding. Mol Immunol. 1989 Jun;26(6):523–529. doi: 10.1016/0161-5890(89)90003-5. [DOI] [PubMed] [Google Scholar]
  18. Häyrinen J., Jennings H., Raff H. V., Rougon G., Hanai N., Gerardy-Schahn R., Finne J. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis. 1995 Jun;171(6):1481–1490. doi: 10.1093/infdis/171.6.1481. [DOI] [PubMed] [Google Scholar]
  19. Jennings H. J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol. 1986 Sep 1;137(5):1708–1713. [PubMed] [Google Scholar]
  20. Jennings H. J., Roy R., Michon F. Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. J Immunol. 1985 Apr;134(4):2651–2657. [PubMed] [Google Scholar]
  21. Johnson J. R. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev. 1991 Jan;4(1):80–128. doi: 10.1128/cmr.4.1.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kabat E. A., Liao J., Osserman E. F., Gamian A., Michon F., Jennings H. J. The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgMNOV. J Exp Med. 1988 Aug 1;168(2):699–711. doi: 10.1084/jem.168.2.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kaijser B. Immunology of Escherichia coli: K antigen and its relation to urinary-tract infection. J Infect Dis. 1973 Jun;127(6):670–677. doi: 10.1093/infdis/127.6.670. [DOI] [PubMed] [Google Scholar]
  24. Kasper D. L., Winkelhake J. L., Zollinger W. D., Brandt B. L., Artenstein M. S. Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol. 1973 Jan;110(1):262–268. [PubMed] [Google Scholar]
  25. Lifely M. R., Roberts S. C., Shepherd W. M., Esdaile J., Wang Z., Cleverly A., Aulaqi A. A., Moreno C. Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins. Vaccine. 1991 Jan;9(1):60–66. doi: 10.1016/0264-410x(91)90318-z. [DOI] [PubMed] [Google Scholar]
  26. Mandrell R. E., Azmi F. H., Granoff D. M. Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J Infect Dis. 1995 Nov;172(5):1279–1289. doi: 10.1093/infdis/172.5.1279. [DOI] [PubMed] [Google Scholar]
  27. Mandrell R. E., Zollinger W. D. Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants. J Immunol. 1982 Nov;129(5):2172–2178. [PubMed] [Google Scholar]
  28. Moreno C., Lifely M. R., Esdaile J. Effect of aluminum ions on chemical and immunological properties of meningococcal group B polysaccharide. Infect Immun. 1985 Sep;49(3):587–592. doi: 10.1128/iai.49.3.587-592.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Perera A. D., Lagenaur C. F., Plant T. M. Postnatal expression of polysialic acid-neural cell adhesion molecule in the hypothalamus of the male rhesus monkey (Macaca mulatta). Endocrinology. 1993 Dec;133(6):2729–2735. doi: 10.1210/endo.133.6.7694845. [DOI] [PubMed] [Google Scholar]
  30. Raff H. V., Devereux D., Shuford W., Abbott-Brown D., Maloney G. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections. J Infect Dis. 1988 Jan;157(1):118–126. doi: 10.1093/infdis/157.1.118. [DOI] [PubMed] [Google Scholar]
  31. Roth J., Taatjes D. J., Bitter-Suermann D., Finne J. Polysialic acid units are spatially and temporally expressed in developing postnatal rat kidney. Proc Natl Acad Sci U S A. 1987 Apr;84(7):1969–1973. doi: 10.1073/pnas.84.7.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Saukkonen K., Haltia M., Frosch M., Bitter-Süerman D., Leinonen M. Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo. Microb Pathog. 1986 Feb;1(1):101–105. doi: 10.1016/0882-4010(86)90036-7. [DOI] [PubMed] [Google Scholar]
  33. Schneerson R., Robbins J. B., Chu C., Sutton A., Vann W., Vickers J. C., London W. T., Curfman B., Hardegree M. C., Shiloach J. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun. 1984 Sep;45(3):582–591. doi: 10.1128/iai.45.3.582-591.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Weinberg G. A., Einhorn M. S., Lenoir A. A., Granoff P. D., Granoff D. M. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr. 1987 Jul;111(1):22–27. doi: 10.1016/s0022-3476(87)80336-0. [DOI] [PubMed] [Google Scholar]
  35. Wyle F. A., Artenstein M. S., Brandt B. L., Tramont E. C., Kasper D. L., Altieri P. L., Berman S. L., Lowenthal J. P. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972 Nov;126(5):514–521. doi: 10.1093/infdis/126.5.514. [DOI] [PubMed] [Google Scholar]
  36. Zollinger W. D., Boslego J. E., Frasch C. E., Froholm L. O. Safety of vaccines containing meningococcal group B polysaccharide. Lancet. 1984 Jul 21;2(8395):166–166. doi: 10.1016/s0140-6736(84)91083-3. [DOI] [PubMed] [Google Scholar]
  37. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Zollinger W. D., Moran E. E., Devi S. J., Frasch C. E. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect Immun. 1997 Mar;65(3):1053–1060. doi: 10.1128/iai.65.3.1053-1060.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES